Patient Perceptions of Exertion and Dyspnea With Interleukin-1 Blockade in Patients With Recently Decompensated Systolic Heart Failure
Introduction
Cardiopulmonary exercise testing (CPET) is the gold standard assessment of cardiorespiratory fitness (CRF) in heart failure (HF).1, 2, 3, 4 CPET offers a unique opportunity to measure objective parameters that are both “disease-oriented” prognostic markers and “patient-oriented” functional assessments. Peak oxygen consumption (VO2) and the minute ventilation/carbon dioxide production (VE/VCO2) slope represent powerful independent predictors of adverse cardiovascular outcomes that have been widely used to measure prognosis, disease progression, exercise capacity, and more broadly, CRF.5 Despite these important insights, however, these metrics do not directly incorporate patient perceptions of dyspnea and exertion during submaximal exercise. Given that patients with HF spend the majority of their lives and experience the majority of clinical symptoms at submaximal levels of physical exertion, we investigated the utility of patient ratings of perceived exertion (RPE) and dyspnea on exertion (DOE) at standardized times during CPET as a measure of treatment response within the setting of the REDHART (Recently Decompensated Heart Failure Anakinra Response Trial) clinical trial, a study of targeted interleukin-1 (IL-1) blockade in patients with systolic HF.6,7
Section snippets
Methods
The design of the REDHART clinical trial was previously presented elsewhere.7 In brief, REDHART was a randomized, placebo-controlled, double-blinded, experimental trial to evaluate the use of recombinant IL-1 receptor antagonist (anakinra) on CRF (in particular, the peak VO2 and the VE/VCO2 slope) in 60 patients enrolled within 2 weeks of hospitalization for acute decompensated systolic HF. Patients were randomized (1: 1: 1) to subcutaneous injections of anakinra 100 mg per day for 12 weeks,
Results
The clinical characteristic of the patients in the 3 groups have been already described.7 All CPETs were completed to maximal exertion and 92% of all CPETs achieved peak RER ≥1.00 (median peak RER = 1.13 [interquartile range [IQR] 1.06 to 1.20]). Patient demographic data including cardiovascular risk factors did not show a significant difference between groups (Table 1). There were no significant differences in the use of HF medications among groups, except for the use of hydralazine/isosorbide
Discussion
Improving the burden of HF symptoms remains an unmet medical need. Even in the absence of symptoms at rest, many patients with HF experience frequent symptoms of dyspnea and fatigue with low levels of exertion that disrupt activities of daily living and significantly impair quality of life. Patient-reported outcomes, measured with the MLHFQ and DASI, capture the severity of HF symptoms and carry important prognostic information.9,15 CPET is a noninvasive test that assesses a broad array of
Disclosures
Dr. Van Tassell and Dr. Abbate were co-prinicpal investigators on the NIH funding for this study. Please list both of them as receiving financial support from NIH.
References (31)
- et al.
Exercise intolerance in patients with heart failure: JACC state-of-the-art review
J Am Coll Cardiol
(2019) - et al.
Determinants of cardiorespiratory fitness in patients with heart failure across a wide range of ejection fractions
Am J Cardiol
(2020) - et al.
Effects of respiratory exchange ratio on the prognostic value of peak oxygen consumption and ventilatory efficiency in patients with systolic heart failure
JACC Heart Fail
(2013) - et al.
Cardiopulmonary exercise testing versus 6-Min walk test as clinically meaningful endpoints in HF trials
J Am Coll Cardiol
(2017) - et al.
Ventilatory efficiency and dyspnea on exertion improvements are related to reduced pulmonary pressure in heart failure patients receiving sildenafil
Int J Cardiol
(2010) - et al.
Predictive value of cardiopulmonary exercise testing parameters in ambulatory advanced heart failure
JACC Heart Fail
(2021) - et al.
Usefulness of canakinumab to improve exercise capacity in patients with long-term systolic heart failure and elevated C-reactive protein
Am J Cardiol
(2018) - et al.
Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)
Am J Cardiol
(2014) - et al.
Prognostic value of cardiopulmonary exercise testing in idiopathic dilated cardiomyopathy
Int J Cardiol
(2016) - et al.
Cardiopulmonary exercise testing - refining the clinical perspective by combining assessments
Expert Rev Cardiovasc Ther
(2020)
C-reactive protein and N-terminal pro-brain natriuretic peptide levels correlate with impaired cardiorespiratory fitness in patients with heart failure across a wide range of ejection fraction
Front Cardiovasc Med
Reduced exercise capacity and clinical outcomes following acute myocardial infarction
Heart Vessels
Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease
Circ Res
Interleukin-1 blockade in recently decompensated systolic heart failure: results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial)
Circ Heart Fail
Using the Duke Activity Status Index in heart failure
J Cardiopulm Rehabil
Cited by (1)
This study was supported by R34HL117026 and UL1TR000058 for NIH (Bethesda, Maryland).